CA2737855A1 - Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy - Google Patents

Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy Download PDF

Info

Publication number
CA2737855A1
CA2737855A1 CA2737855A CA2737855A CA2737855A1 CA 2737855 A1 CA2737855 A1 CA 2737855A1 CA 2737855 A CA2737855 A CA 2737855A CA 2737855 A CA2737855 A CA 2737855A CA 2737855 A1 CA2737855 A1 CA 2737855A1
Authority
CA
Canada
Prior art keywords
hydroxy
cancer
group
compound
methoxybenzoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2737855A
Other languages
English (en)
French (fr)
Inventor
Robert Kiss
Jacques Dubois
Jean Neve
Delphine Lamoral-Theys
Francois Dufrasne
Laurent Pottier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Libre de Bruxelles
Original Assignee
Université Libre de Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Libre de Bruxelles filed Critical Université Libre de Bruxelles
Publication of CA2737855A1 publication Critical patent/CA2737855A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/88—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2737855A 2008-10-17 2009-10-13 Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy Abandoned CA2737855A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US10625108P 2008-10-17 2008-10-17
EP08166852.7 2008-10-17
EP08166852 2008-10-17
US61/106,251 2008-10-17
US16643909P 2009-04-03 2009-04-03
US61/166,439 2009-04-03
EP09157289 2009-04-03
EP09157289.1 2009-04-03
PCT/EP2009/063369 WO2010043631A1 (en) 2008-10-17 2009-10-13 Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy

Publications (1)

Publication Number Publication Date
CA2737855A1 true CA2737855A1 (en) 2010-04-22

Family

ID=41591654

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2737855A Abandoned CA2737855A1 (en) 2008-10-17 2009-10-13 Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy

Country Status (6)

Country Link
US (1) US20110280940A1 (enExample)
EP (1) EP2367545A1 (enExample)
JP (1) JP2012505855A (enExample)
AU (1) AU2009305450A1 (enExample)
CA (1) CA2737855A1 (enExample)
WO (1) WO2010043631A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158112A1 (en) * 2011-06-20 2013-06-20 Jonathan D. SMITH Compositions and methods for inhibiting beta amyloid secretion
US20130164228A1 (en) * 2011-12-21 2013-06-27 Colgate-Palmolive Company Compositions comprising gallates and gallamides
WO2014144952A2 (en) 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
WO2015130947A1 (en) * 2014-02-26 2015-09-03 Howard University Benzende sulfonamide derivatives as hiv integrase inhibitors
CN106029632B (zh) * 2014-02-28 2019-06-21 国立大学法人东北大学 酰胺衍生物
ES2566430B1 (es) * 2014-09-12 2017-01-26 Instituto Aragones De Ciencias De La Salud Esteres de di-benzoato y su uso terapéutico como moduladores negativos de canales de potasio KCa2/3
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
EP4306166A3 (en) * 2016-12-23 2024-06-26 Aquinnah Pharmaceuticals Inc. Compounds, compositions and methods of use
CN108456148B (zh) * 2018-05-09 2020-09-25 陕西理工大学 N-(3,4,5-三羟基苯甲酰)-3,4,5-三羟基苯甲酰胺及其制备方法与应用
CA3203741A1 (en) * 2021-01-20 2022-07-28 Beam Therapeutics Inc. Nanomaterials comprising an ionizable lipid
CN113620831B (zh) * 2021-07-21 2023-09-05 天津大学 抑制淀粉样β蛋白聚集的小分子化合物和制备方法及其应用
DE102021212696A1 (de) 2021-11-11 2023-05-11 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein Stabilisatoren auf Basis von Syringasäure, Vanillinsäure, lsovanillinsäure oder 5-Hydroxyveratrumsäure, Kunststoffzusammensetzung, Verfahren zur Stabiliserung einer Kunststoffzusammensetzung sowie Stabilisatorzusammensetzung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362510A (en) * 1981-12-10 1982-12-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cementitious dental compositions which do not inhibit polymerization
JP3348464B2 (ja) * 1993-05-06 2002-11-20 吉富ファインケミカル株式会社 ヒドロキシ安息香酸エステル類の精製法
JPH07118209A (ja) * 1993-10-25 1995-05-09 Fuji Photo Film Co Ltd 没食子酸エステル誘導体及びそれを使用した記録材料
JP2002006437A (ja) * 2000-06-19 2002-01-09 Fuji Photo Film Co Ltd ハロゲン化銀感光材料、感光性平版印刷原版およびレリーフ画像形成方法
US6713506B2 (en) * 2000-10-11 2004-03-30 University Of South Florida Tea polyphenol esters and analogs thereof for cancer prevention and treatment
PT1511710E (pt) * 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
JP2004035484A (ja) * 2002-07-04 2004-02-05 Mitsui Chemicals Inc シクロヘキサンジアミン誘導体
JP2004217600A (ja) * 2003-01-17 2004-08-05 Shionogi & Co Ltd 一酸化窒素合成酵素阻害剤
US7358383B2 (en) * 2003-01-24 2008-04-15 University Of South Florida Polyphenol proteasome inhibitors, synthesis, and methods of use

Also Published As

Publication number Publication date
JP2012505855A (ja) 2012-03-08
WO2010043631A1 (en) 2010-04-22
US20110280940A1 (en) 2011-11-17
EP2367545A1 (en) 2011-09-28
AU2009305450A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
US20110280940A1 (en) Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy
US9168247B2 (en) Beta carboline derivatives useful in the treatment of proliferative disorders
TWI620563B (zh) 用於治療癌症的化合物及組成物
US20070213319A1 (en) Modulators of hepatocyte growth factor/c-Met activity
JP2013520490A (ja) オキサジアゾール化合物、ならびにそれらの製造および用途
WO2020155931A1 (zh) 一种jak抑制剂及其制备方法
CN105980372A (zh) 官能化的苯并吡喃化合物及其用途
JP5235257B2 (ja) 治療化合物としての置換カルコン
ES2291378T3 (es) Compuestos derivados de dihidronaftaleno y medicamentos que utilizan estos compuestos como ingrediente activo.
WO2012022780A1 (en) 18-beta-glycyrrhetinic acid derivatives with anti-tumor activity
CN104211682B (zh) 吡啶类化合物及其用途
JP2022527279A (ja) キノリン誘導体及び癌の治療のためのその使用
CN101516823A (zh) 用于治疗认知性、神经变性或神经元性疾病或病症的苯基-异戊二烯基-醚衍生物
US9771344B2 (en) Peloruside analogs
CN101245061B (zh) N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶胺类一氧化氮供体型衍生物，制备方法及其用途
KR102801295B1 (ko) 골질환의 예방 또는 치료용 약학 조성물
CN106946851B (zh) 一种用于预防和治疗肾结石的药物
CN104230611B (zh) 一种4-(1-取代苯基乙烯基)联苯衍生物及其制备方法和应用
HK1227740A (en) Compounds and compositions for the treatment of cancer
HK1227740A1 (en) Compounds and compositions for the treatment of cancer
HK1227740B (en) Compounds and compositions for the treatment of cancer
HK1189836B (en) Compounds and compositions for the treatment of cancer

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20151014